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ABSTRACT 33 
Objectives  34 
 The corticotrophin-releasing factor (CRF)/urocortin system is expressed in the adipose 35 
tissue of mammals but its functional role in this tissue remains unknown. 36 
 37 
Methods 38 
 Pharmacological manipulation of CRF-Receptors, CRF1 and CRF2, activity was 39 
performed in 3T3L1 white pre-adipocytes and T37i brown pre-adipocytes during in vitro 40 
differentiation. The expression of genes of the CRF/Urocortin system and of markers of white 41 
and brown adipocytes was evaluated along with mitochondrial biogenesis and cellular oxygen 42 
consumption. Metabolic evaluation of corticosterone-deficient or supplemented Crhr null 43 
(Crhr-/-) mice and their wild-type controls was performed along with gene expression analysis 44 
carried out in white (WAT) and brown (BAT) adipose tissues.  45 
 46 
Results  47 
 Peptides of the CRF/Urocortin system and their cognate receptors were expressed in 48 
both pre-adipocyte cell lines. In vitro pharmacological studies showed an inhibition of the 49 
expression of the CRF2 pathway by the constitutive activity of the CRF1 pathway. 50 
Pharmacological activation of CRF2 and, to a lesser extent, inhibition of CRF1 signaling 51 
induced molecular and functional changes indicating transdifferentiation of white pre-52 
adipocytes and differentiation of brown pre-adipocytes. Crhr-/- mice showed increased 53 
expression of CRF2 and its agonist Urocortin 2 in adipocytes that was associated to brown 54 
conversion of WAT and activation of BAT. Crhr-/- mice were resistant to diet-induced obesity 55 
and glucose intolerance. Restoring physiological circulating corticosterone levels abrogated 56 
molecular changes in adipocytes and the favorable phenotype of Crhr-/- mice. 57 
 58 
Conclusions 59 
 Our findings suggest the importance of the CRF2 pathway in the control of adipocyte 60 
plasticity. Increased CRF2 activity in adipocytes induces browning of WAT, differentiation of 61 
BAT and is associated with a favorable metabolic phenotype in mice lacking CRF1. 62 
Circulating corticosterone represses CRF2 activity in adipocytes and may thus regulate 63 
adipocyte physiology through the modulation of the local CRF/Urocortin system. Targeting 64 
CRF-receptor signaling specifically in the adipose tissue may represent a novel approach to 65 
tackle obesity. 66 
Keywords: CRF, urocortin, white adipose tissue, brown adipose tissue, CRF1, CRF2, obesity, 67 
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adipocyte plasticity  68 
 69 
Introduction  70 
The corticotrophin-releasing factor (CRF)/urocortin system is a complex 71 
neuroendocrine system that includes four structurally related peptides [CRF, and urocortins -1, 72 
-2 and -3] and two seven-transmembrane domain receptors, CRF1 and CRF2, which mediate 73 
the physiological effects of these peptides (1). CRF is a preferential CRF1 ligand, while 74 
urocortin 1 has high affinity for both receptors and urocortin 2 and -3 are specific for CRF2. 75 
Apart from its pivotal role in orchestrating responses to stress, the CRF/urocortin system also 76 
regulates energy balance (1-5). Proposed effects include modulation of energy expenditure, 77 
fuel partitioning and metabolism through various mechanisms, including the regulation of the 78 
sympathetic nervous system (SNS) activity and of glucocorticoid secretion, as well as 79 
regulation of food intake (1-3; 5).  80 
The distinct anatomical distributions of CRF1 and CRF2 imply diverse physiological 81 
functions. Although the relative contribution of the two receptors in energy homeostasis 82 
remains debatable, emerging evidence suggests an independent and prominent role of the CRF2 83 
pathway in the CNS to regulate feeding, glucose metabolism and thermoregulation (1; 3; 5; 6). 84 
CRF2 pattern of expression suggests that this receptor may also participate in the regulation of 85 
energy balance in key peripheral tissues involved in energy metabolism and modulate fuel 86 
utilization by acting locally through paracrine mechanisms at the level of pancreatic β- and 87 
skeletal muscle cells (7-9).  88 
CRF, urocortins and CRF-R are expressed in the white adipose tissue of various 89 
species, including human subcutaneous and visceral white adipocytes (1; 10-13). The 90 
functional role of CRF-R in the adipose tissue remains unknown. Only one pharmacological 91 
study found that activation of the CRF2 reduces lipolysis in mature human subcutaneous white 92 
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adipocytes (14). Therefore, the purpose of the present study was to investigate the functional 93 
relevance of CRF-R pathways in the adipose tissue. 94 
 95 
MATERIALS AND METHODS 96 
Total RNA extraction and quantitative RT-PCR (qPCR) 97 
Samples (inguinal white adipose tissue, interscapular brown adipose tissue, 3T3-L1 and T37i 98 
cells) were homogenized with lysis buffer and total RNA was extracted using Qiagen 99 
RNeasyTM Lipid Tissue Mini Kit, according to the manufacturer’s instructions. Extracted total 100 
RNA was reverse-transcribed into cDNA by two-step reverse transcription PCR using 101 
SuperScriptTM II Reverse Transcriptase. QPCR was carried out using a Light CyclerTM system 102 
(Roche Molecular Biochemicals Germany). The qPCR primers are listed in Supplemental 103 
Table 1. The reaction was carried out in a 10 μl of reaction mixture containing 5 μl PCR 2 x 104 
Mastermix with 2 mM MgCl2, 0.5 μl Light Cycler DNA Master SYBER®Green I, 1 μl of each 105 
primer (2 μg/ μl), and 1 μl cDNA. The qPCR protocol consisted of a denaturation step at 95C 106 
for 15 sec, following by 40 cycles of amplification at 95C for 5 sec, 58C for 10 sec, 72C for 107 
15 sec, and finally by a melting curve analysis step at 95C for 10 sec, 56C for 15 sec, and 108 
99C for 10 sec. Quantitative amounts of gene of interest were standardized against the 109 
housekeeping genes β-actin and GAPDH. Preparations lacking RNA or reverse transcriptase 110 
were used as negative controls. RNA expression was tested in 4 independent experiments. 111 
mRNA relative level of expression was calculated using the comparative (2-∆∆CT) method.  112 
 113 
3T3-L1 and T37i cell cultures  114 
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3T3-L1 cells were differentiated in growth medium (DMEM/F12 medium containing 10% 115 
BCS, 100 U/ml penicillin and 100 mg/ml streptomycin) and 15 nM HEPES with 1 g/l glucose. 116 
Differentiation was induced by incubation with 10% FBS with 5 μg/ml insulin , 0.25 μM 117 
dexamethasone, and 0.5 mM IBMX for 2 days before return to growth medium. 3T3-L1 fully 118 
differentiated within 6-10 days. T37i cells were cultured in DMEM/F12 medium with 10% 119 
FBS, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, and 15 nM HEPES 120 
with 1 g/l glucose. Differentiation was achieved by incubating sub-confluent undifferentiated 121 
T37i cells with 2nM triiodothyronine and 20 nM insulin for 8-12 days. In some experiments, 122 
3T3L1 preadipocytes were exposed to CRF (100 nM), urocortin 2 (100 nM), and/or the CRF1 123 
antagonist NBI 27914 (1 µM) for various time periods (2, 4, 6 or 8 days). At the end of the 124 
required period, cells were washed with ice-cold PBS and lysed in RNA extraction buffer. 125 
Extracted RNA was further processed by qPCR.  126 
Immunocytochemistry 127 
Adipose tissue samples were fixed for 16-24 hr in 4% paraformaldehyde (PFA) at 4C, 128 
paraffin embedded and cut at 7m using a microtome (Leica Microsystems, USA). Fixed 129 
tissues were washed with filter-sterilized PBS. Non-specific banding was blocked with 3% 130 
BSA in PBS-Triton X-100 (0.01%) for 1h.  131 
For cell fixation, round glass cover slips (25 mm) were treated with acetic acid for 30 min, 132 
then with 70% ethanol for 30 min, and acetone containing 200 l 3-(aminopropyl) triethoxy 133 
saline (APES). Prior to use, the plates were sterilized by UV radiation for 30 min. The cover 134 
slips were coated with 100 g/ml poly-D-lysine in PBS. After 10 min soaking, cover slips 135 
were washed with filter sterilized PBS. Confluent cells were trypsinized, and resuspended in 136 
15 ml of media. 100-150 l  of cells were left on a cover slip for 20 min, and 4 ml medium 137 
was added. When appropriate, media were removed from the wells, and cells were briefly 138 
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washed with PBS and fixed with 0.5 ml of 4% PFA in PBS for 30 min. After washing with 139 
PBS, cells were processed for immunostaining. 140 
After 3 washes with PBS, slides were incubated overnight at 4C with primary 141 
antibodies (1:50 and 1:100) for COXIV, (Invitrogen, Paisly, UK) or UCP1 (Abcam, 142 
Cambridge, UK). Then slides were washed with PBS and incubated with secondary antibodies 143 
(donkey anti-rabbit Alexa-Fluor®488) for 1h at RT. Sections were mounted with VectaShield® 144 
Hard SetTM mounting medium. Samples were examined under an oil immersion objective using 145 
Leica model DMRE laser scanning confocal microscope with TCS SP2 scan head. Between 30 146 
to 35 individual cells in 6 random fields of view were selected and analyzed. The scan speed 147 
was 400 Hz, and the format was 1024 x 1024 pixels. No specific fluorescence was observed in 148 
cells treated only with the secondary antibody. The images were manipulated with Leica and 149 
Image J (National Institute of Health, Bethesda, Maryland, USA) software.  150 
Cellular respiration assay 151 
3T3L1 preadipocytes were exposed to CRF (100 nM), Urocortin 2 (100 nM), isoproterenol (1 152 
µM) and NBI 27914 (1 µM). On days 4 and 8 of cell differentiation, measurements of the 153 
oxygen concentration were made over 1 to 2 min using the Seahorse XF24 instrument 154 
(Seahorse Bioscience) and the rates of oxygen consumption were determined. DMSO was used 155 
as vehicle throughout the Seahorse respiration assays.  Cells were equilibrated in the medium 156 
at 37C for 30 min, and then baseline metabolic rates were measured over the next 30 min and 157 
were reported in nM/min of the oxygen consumption rate. Results were normalized to total 158 
protein level.  159 
Animal procedures 160 
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All experiments involving animals were conducted in strict compliance with the European 161 
Union recommendations (2010/63/EU) and were approved by the French Ministry of 162 
Agriculture and Fisheries (animal experimentation authorization n° 3309004). 163 
Housing and Diets 164 
Crhr deficient mice (Crhr-/-) on a C57BL ⁄ 6Jx129Sv-Ter genetic background were generated 165 
and genotyped as previously described (15) and their WT (Crhr+/+) littermates used as 166 
controls. Experiments were performed in 7-8 months individually housed male mice under a 167 
12/12h light/dark cycle and controlled temperature (23°C). The regular chow diet contained 168 
9.5% Kcal as fat with an energy density of 2.9 Kcal/g (AO4, UAR). The HF diet contained 169 
45% Kcal as fat with an energy density of 4.73 Kcal/g (N° 12450B, Research Diets). Food 170 
intake and body weight were recorded and feed efficiency calculated as body gain weight 171 
(g)/total caloric intake (100/Kcal). Corticosterone (SIGMA-Aldrich) was supplemented at 172 
5µg/ml in drinking water while Crhr+/+ mice received the vehicle only (0.2% ethanol in 173 
drinking water). 174 
Body Composition  175 
Whole body composition was evaluated by dual energy X-ray absorptiometry (Piximus, 176 
General Electric).  177 
Locomotor activity  178 
Locomotor activity of Crhr-/- and Crhr+/+ littermates was evaluated using individual locomotor 179 
activity cages with two levels photocell beams allowing recording of both horizontal 180 
(locomotion) and vertical (rearing) behaviour (Imetronic). Mice were housed for 22h a day for 181 
3 days for habituation and then locomotor activity was recorded.  182 
Plasma measurements 183 
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Blood samples were collected by tail bleeding in heparinized capillary tubes. Blood samples 184 
for corticosterone measurement were obtained 1 h before the onset of the dark phase within 1 185 
min of removal of mice from their cage. Corticosterone, leptin and insulin were measured 186 
using immunoassays (ICN Pharmaceuticals and Linco). Triglycerides were measured using an 187 
enzymatic kit (PAP 150 kit, bioMerieux). Plasma catecholamines were measured by HPLC as 188 
previously described (16). Whole β-hydroxybutyrate was measured using the β-189 
hydroxybutyrate deshydrogenase method (17). For the glucose tolerance test (GTT), mice 190 
were tested in the morning after an overnight fast. Glucose (2 g/kg in saline) was administered 191 
ip and tail blood collected immediately before and 30, 60, 90 and 120 min after injection. 192 
Glucose was measured using a Lifescan One Touch glucometer (Johnson and Johnson). 193 
HOMA-IR was calculated using the formula [insulin (mU/L) x glucose (mg/dl)]/405. 194 
Statistics  195 
Data are presented as mean  SEM. Data were tested for homogeneity and comparison 196 
between groups was performed by Student’s unpaired t-test with Prism software (GraphPad). 197 
For multiple comparison tests, ANOVA followed by Dunnett test was used. For data with non-198 
normal distribution, the Kruskal-Wallis ANOVA followed by Bonferroni test was used. 199 
P<0.05 was considered significant. 200 
 201 
RESULTS  202 
 203 
Regulation of the adipocyte CRF/urocortin system in vitro.  204 
To determine the role of the CRF/urocortin system in adipocytes, we first investigated 205 
the expression of CRF1 and -R2 and the impact of their pharmacological manipulation in 206 
3T3L1 white pre-adipocytes or T37i brown pre-adipocytes (18; 19). CRF1 and CRF2 as well as 207 
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CRF, Urocortin 1 and Urocortin 2 mRNAs were detected in both cell lines (Figures 1A and 208 
2A). Treatment of 3T3L1 cells with CRF increased CRF1 mRNA expression only (Figure 1A). 209 
Differently, treatment with the specific CRF2 agonist Urocortin 2 during differentiation 210 
stimulated mRNA expression of CRF and of the CRF2 pathway components Urocortin 2 and 211 
CRF2 (Figure 1A). Inhibition of the endogenous CRF1 activity by the specific CRF1 antagonist 212 
NBI-27914 mimicked the effects of Urocortin 2, suggesting that activity of the CRF1 pathway 213 
spontaneously represses the CRF2 pathway. Roughly similar changes were also induced in the 214 
brown adipocyte precursors T37i cells (Figure 2A). 215 
 216 
CRF1 and CRF2 pathways differently regulate in vitro the transcriptional machinery 217 
promoting the brown adipocyte phenotype.  218 
During 3T3L1 cells differentiation, activation of the CRF2 pathway by Urocortin 2 219 
dramatically increased mRNA expression of PRDM16 and BMP7, two key factors inducing 220 
brown adipocyte phenotype and able to stimulate beige adipocyte differentiation (20-22) 221 
(Figure 1B). Furthermore, Urocortin 2 increased the mRNA expression of PGC1-α and of 222 
UCP1, two markers of brown or beige adipocyte activation (20; 21) (Figure 1B). Similar 223 
effects, albeit less potent, were induced by the β-receptor agonist isoproterenol, a strong 224 
activator of BAT thermogenesis that induces ectopic expression of UCP1 in WAT (23). 225 
 While simulating the expression of brown fat-promoting genes, Urocortin 2 inhibited 226 
the differentiation-dependent induction of the white adipocyte gene markers leptin, Wdnm1, 227 
resistin and chemerin (Figure 1B). Conversely, exposure of 3T3L1 cells to the preferential 228 
CRF1 agonist CRF during differentiation did not induce expression of brown fat-promoting 229 
genes, but enhanced by 4 to 20 fold the expression of the aforementioned white adipocyte gene 230 
markers (Figure 1B). Blockade of CRF1 by NBI-27914 mimicked, although less potently, the 231 
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effects of Urocortin 2 (Figure 1B). Similarly, Urocortin 2 induced the expression of molecular 232 
markers characteristic of brown adipocyte differentiation in T37i cells (Figure 2B). 233 
Activation of the CRF2 pathway and inhibition of the CRF1 pathway induces 234 
functional changes consistent with the browning of white preadipocytes 235 
To further investigate the opposing actions of CRF1 and CRF2 pathways on the white 236 
pre-adipocyte transcriptional machinery, we studied the functional consequences of 237 
pharmacological manipulations of CRF-Rs on mitochondrial biogenesis in 3T3L1 cells. 238 
Urocortin 2 and, to a lesser extent, NBI-27914 increased protein expression of COXIV, a 239 
marker of mitochondrial biogenesis in a time-dependent manner (Figure 1C). To determine 240 
whether these molecular changes were associated with changes in cellular metabolism, we 241 
measured oxygen consumption rate (OCR) in stimulated 3T3L1 cells. Treatment with Urocotin 242 
2 during differentiation enhanced OCR, whereas CRF had no effect (Figure 1D). NBI-27914 243 
mimicked to a lesser extent the effects of Urocortin 2 (Figure 1D). Whereas the combination of 244 
these two drugs had no additive effect over Urocortin 2-induced OCR (data not show). These 245 
results are therefore consistent with increased mitochondrial respiration confirming the 246 
transdifferentiation of white preadipocytes towards metabolically activated “beige” adipocytes 247 
(20; 21; 24; 25) as the result of the activation of the CRF2 pathway and, to a lesser extent, to 248 
the inhibition of the CRF1 pathway.  249 
These findings therefore identify divergent roles for CRF1 and -R2 pathways in pre-250 
adipocyte differentiation and pinpoint the importance of the local interplay between the CRF1 251 
and CRF2 pathways regulating adipocyte precursors fate in vitro. 252 
 253 
Increased CRF2 activity in Crhr
-/- mice induces browning of WAT in vivo that is 254 
reversed by corticosterone. 255 
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To confirm the hypothesis that unimpeded CRF2 activity induces brown conversion of 256 
WAT in vivo, we performed complementary studies in Crhr-/-  and their Crhr+/+ littermates. 257 
Deletion of Crhr decreases ACTH and corticosterone secretion (15). We therefore also studied 258 
Crhr-/- mice supplemented with corticosterone in drinking water.  259 
As expected, plasma corticosterone at the time of the diurnal peak in Crhr-/- mice was 260 
decreased compared to that of Crhr+/+ mice  (3.9 ± 0.5 ng/ml vs. 23.8 ± 3.85 ng/ml 261 
respectively, p < 0.001) while it was restored to physiological levels in steroid-supplemented 262 
Crhr-/- mice (Crhr-/- Cort) (27.3 ± 5.6 ng/ml). Since Crhr deletion induces variable alterations 263 
in the expression of other components of the CRF/urocortin system within tissues (11; 26), we 264 
carried out gene expression analysis in the adipose tissue of Crhr-/- mice. Molecular changes in 265 
the inguinal WAT of Crhr-/- mice were similar to those induced by the pharmacological 266 
inhibition of the CRF1 pathway in 3T3L1 cells, including a 3 to 4 fold increase in CRF, 267 
Urocortin 2 and CRF2 mRNA expression (Figure 3A). Urocortin 2 and CRF2 protein 268 
expression was also increased (Figure 3A, right panels). Similar changes were observed in the 269 
BAT (Figure 4A). Interestingly, mRNA levels of CRF, Urocortin 2 and CRF2 in WAT and 270 
BAT were comparable between Crhr+/+ and Crhr-/- Cort mice, suggesting that the upregulation 271 
in urocortin 2 and CRF2 expression induced by the lack of CRF1 signaling in vivo is secondary 272 
to the reduced levels of circulating corticosterone.  273 
Similarly to our in vitro findings, genes involved in determining the beige phenotype 274 
were upregulated in the inguinal WAT of Crhr-/- mice, while the expression of WAT-specific 275 
genes was strongly decreased (Figure 3B). These changes were associated with a dramatic 276 
increase in the expression of UCP1 and COXIV proteins, confirming the browning of WAT 277 
(Figure 3C). Up-regulation of brown-adipocyte gene markers was also observed in the BAT of 278 
Crhr-/- mice (Figure 4B). Importantly, 3-adrenergic receptor expression in inguinal WAT and 279 
BAT (data not shown) and plasma levels of norepinephrine (Crhr+/+: 13.3 ± 1.5 μg/l vs. Crhr-/-: 280 
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14.9 ± 1.2 μg/l, p=N.S.) did not differ between genotypes. As already reported elsewhere (27), 281 
plasma epinephrine levels were lower in Crhr-/- than in Crhr+/+ mice (3.2 ±0.4 μg/l vs. 15.5 ± 282 
2.9 μg/l respectively; p<0.001). Corticosterone supplementation in Crhr-/- mice completely 283 
prevented the molecular changes suggestive of WAT browning (Figure 3, B and C) and 284 
activation of BAT (Figure 4B).  285 
 286 
Crhr-/- mice display a lean phenotype and resistance to high-fat (HF) diet that is 287 
reversed by physiological circulating levels of corticosterone. 288 
To determine the in vivo metabolic impact of the above-described changes, we further 289 
characterized Crhr-/- mice. Adult Crhr-/- mice maintained on regular chow displayed similar 290 
weight as compared to their Crhr+/+ littermates, but had a decrease in fat mass and an 291 
associated increase in lean mass (supplementary figure 1, A-D). The reduced adiposity could 292 
not be explained by differences in food intake or locomotor activity (supplementary figure 293 
figure 1, E and F). Crhr-/- mice displayed reduced fasting plasma insulin concentrations, 294 
although glucose tolerance was similar between genotypes (supplementary figure figure 1, G 295 
and H). Crhr-/- mice maintained on a HF diet for 50 days showed reduced body weight gain, 296 
adiposity and leptin levels compared to Crhr+/+ mice (Figure 5, A-D). Locomotor activity and 297 
caloric intake were similar between genotypes (Figure 5, E-F) while Crhr-/- mice had decreased 298 
feed efficiency (Figure 5G), suggesting an increase in energy dissipation. Accordingly, Crhr-/- 299 
mice had increased plasma hydroxybutyrate levels (Figure 6H), characteristic of increased fatty 300 
acid oxidation. Crhr-/- mice were also protected from diet-induced metabolic alterations and 301 
had significantly lower fasting HOMA index, lower plasma triglycerides and improved glucose 302 
tolerance as compared to Crhr+/+ mice (Figure 5, H-J). Conversely, the replacement of 303 
physiological levels of corticosterone abolished the protection against the deleterious effects of 304 
a HF diet (Figure 5, A-K). 305 
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DISCUSSION  306 
This study demonstrates that, in vitro, the CRF/urocortin system critically contributes to 307 
regulate the differentiation fate and function of preadipocytes cell lines and, more specifically, 308 
that increased activity of the CRF2 pathway, through local mechanisms, induces 309 
transdifferentiation of white pre-adipocytes to metabolically active beige adipocytes and 310 
promotes differentiation of BAT. These pharmacological results were corroborated in vivo 311 
using Crhr-/- mice in which CRF2 activity is unimpeded and that show molecular evidence of 312 
browning of WAT, activation of BAT and resistance to diet-induced obesity. Our study also 313 
identifies a previously unknown role of circulating corticosterone in hampering the browning 314 
of WAT and activation of BAT through the inhibition of the CRF2 pathway in adipocytes.  315 
In accordance with previously described expression of the CRF/urocortin system in the 316 
adipose tissue of humans and various animal species (1; 10-13), we demonstrate that white and 317 
brown preadipocytes cell lines express the mRNAs of CRF1 and -R2 and their ligands CRF, 318 
Urocortin-1 and Urocortin-2. The increased expression of Urocortin 2 and CRF2 mRNAs after 319 
Urocortin 2 treatment suggests that activation of the CRF2 pathway establishes a positive 320 
feedback loop potentially favoring further auto-activation. Conversely, the increased 321 
expression of the components of the CRF2 pathway observed after treatment with the CRF1 322 
antagonist NBI-27914 implies that the constitutive activity of the CRF1 pathway limits the 323 
expression and function of the CRF2 pathway. Although we did not measure the CRF/urocortin 324 
family peptides in the cell culture media, the local expression of the members of the CRF 325 
system on the one hand and the results of the in vitro pharmacological studies including use a 326 
receptor antagonist on the other suggests a paracrine regulation of the CRF/urocortin system 327 
within the adipocytes. 328 
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Our in vitro experiments demonstrate the ability of the CRF/urocortin system to 329 
regulate the transcriptional machinery governing the differentiation of preadipocyte cell lines. 330 
Divergent roles for CRF1 and -R2 pathways were identified. Activation of CRF2 signaling 331 
stimulated the transcriptional machinery characteristic of the differentiation and activation of 332 
brown adipocytes in both 3T3L1 and T37i cell lines, while inhibiting the induction of white 333 
adipocytes gene markers in white preadipocytes, presumably through the induction of key 334 
transcriptional factors such as BMP7 and PRDM16 (20; 21; 28). Inhibition of CRF1 mimicked, 335 
although to a lesser extent, the consequences of the activation of the CRF2 pathway. The 336 
transformation of white preadipocytes into activated “beige” adipocytes suggested by the 337 
increase in PGC-1α and UCP1 mRNAs and consistent with a transdifferentiation process (24; 338 
25; 29) was confirmed by the increased mitochondrial biogenesis and cellular respiration 339 
induced by CRF2 activation and, to a lesser degree, CRF1 inhibition. Altogether, these in vitro 340 
data suggest that the balance between the CRF1 and CRF2 intracellular signaling in pre-341 
adipocytes play an important role in determining, through paracrine mechanisms, cell 342 
commitment towards divergent differentiation. More specifically in white preadipocyte cell 343 
lines, the CRF2 pathway strongly stimulates the differentiation towards a brown adipocyte 344 
phenotype while activation of the CRF1 pathway by endogenous CRF prevents it, allowing the 345 
expected programmed differentiation towards a white adipocyte phenotype. Notably, several 346 
studies have stressed the importance of the balance between the activity of the CRF1 and CRF2 347 
pathways in the regulation of gastro-intestinal motility, behavioral responses to stressors and 348 
SNS activity (2; 5; 26; 30).  349 
In agreement with our in vitro results, Crhr-/- mice exhibited features suggesting an 350 
unrestrained CRF2 activity, including an increased expression of Urocortin 2 and CRF2 mRNA 351 
levels in inguinal WAT and interscapular BAT. In agreement with the in vitro results observed 352 
after pharmacologically-induced upregulation of CRF2 mRNA expression or direct activation 353 
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of the CRF2 pathway, these changes were associated with an increased expression of the 354 
transcriptional machinery characteristic of brown adipocytes in both WAT and BAT and 355 
decreased expression of the white adipocytes gene markers.  356 
The CRF1 pathway stimulates the activity of the SNS (1; 2; 31). Crhr
-/- mice had similar 357 
levels of 3-adrenergic receptor expression in adipocytes and similar plasma levels of 358 
norepinephrine compared to Crhr+/+ mice. Thus, it is unlikely that the browning of WAT and 359 
activation of BAT observed in Crhr-/- mice results from a local or systemic increase in SNS 360 
activity. However, whether the changes observed in the WAT of Crhr-/- mice represents 361 
recruitment of beige adipocytes or transdifferentiation of white adipocytes deserves further 362 
studies.  363 
In accordance with a functional activation of brown and beige adipocytes through 364 
heightened CRF2 activity, Crhr
-/- mice were obesity resistant and showed features typical of 365 
increased energy dissipation, overall suggesting an important role for the CRF2 pathway in the 366 
regulation of energy balance in vivo. Interestingly, peripheral chronic administration of a CRF2 367 
agonist in rats reduces white fat mass while inducing expression of typical muscle genes in the 368 
WAT (32). Elsewhere, transgenic expression of the CRF2 agonist Ucn3, or in vitro stimulation 369 
of the CRF2 pathway with Urocortin 2 activates energy dissipating substrate cycles in the 370 
muscle and up-regulates UCP2 and UCP3 mRNAs (9; 33). Taking into account that myocytes 371 
and brown adipocytes are derived from a common mesenchymal precursor (28; 34), we might 372 
speculate for a broader role of the CRF2 pathway in promoting mitochondrial thermogenesis in 373 
peripheral tissues, such as the adipose tissue and skeletal muscle. We therefore cannot exclude 374 
at present the involvement of additional mechanisms to the modification of adipocyte activity 375 
to account for the favorable metabolic phenotype of Crhr-/- mice including increased lipid 376 
oxidation in the liver (13). Since our in vitro studies involved pre-adipocyte cell lines and 377 
whole animal studies involved loss-of-function since birth, the effects of manipulation of the 378 
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CRF system after differentiation of adipocytes or during  adulthood remain to be determined. 379 
Complementary studies using chronic infusion of Ucn2 or selective and inducible knockdown 380 
of Crhr1 as well as inducible over expression of Crhr2 or Ucn2 in the adipose tissue will allow 381 
addressing these important mechanistic issues".  382 
Although the importance of glucocorticoids in the differentiation of white preadipocytes 383 
is well acknowledged (18; 19; 35), our experiments also identify a previously unknown role of 384 
corticosterone in white adipocyte biology and energy balance.   385 
Glucocorticoids influence the expression of components of the CRF/urocortin system in 386 
a tissue-selective manner (11; 36; 37). Indeed, corticosterone administration inhibits the 387 
overexpression of Urocortin 2 and CRF2 in the skin (11) and hypothalamus (36) of Crhr
-/- and 388 
adrenalectomized mice. Accordingly, our data suggest a repression of CRF2 activity in white 389 
adipocytes by physiological levels of corticosterone, which allow the expected white adipocyte 390 
differentiation. Conversely, corticosterone deficiency in Crhr-/- mice results in unrestrained 391 
CRF2 activity that promotes the browning of WAT (Figure 6). Concordantly, in vivo reduction 392 
of active glucocorticoids specifically in the adipose tissue of 11β-hydroxysteroid 393 
dehydrogenase type 2 transgenic mice promotes the expression of brown adipocyte markers in 394 
the subcutaneous WAT, decreases the expression of white adipocytes gene markers and is 395 
associated with increased thermogenesis, leading to resistance to diet-induced obesity (38). 396 
Thus, corticosterone should be considered as one of the secreted molecules that is able to 397 
modulate the plasticity of adipose tissue and the induction of beige adipocytes (21). 398 
Complementary studies focusing on the expression of components of the CRF/Ucn system in 399 
the adipose tissue of adrenalectomized mice clamped with various doses of corticosterone and 400 
of mice treated with molecules targeting the 11-hydroxysteroid dehydrogenase in the adipose 401 
tissue are mandatory in order to further dissect the interactions between circulating 402 
corticosterone and adipocytes plasticity 403 
18 
 
Finally, it should be mentioned that recent studies have shown the presence of 404 
functional brown and beige adipocytes in adult humans (24; 39; 40). Stimulating the 405 
thermogenesis of adipose tissue represents a promising strategy to tackle obesity and type 2 406 
diabetes (20; 21; 41-43). In this perspective, our study suggests that the adipocyte CRF2 407 
pathway could be a specific target for the pharmacological treatment of metabolic disease. 408 
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Figure Legend 545 
Figure 1 546 
Modulation of CRF receptors activity during 3T3L1 differentiation induces brown 547 
adipocyte characteristics. (A-B) Activation of CRF2 by 100nM Ucn2 or inhibition of CRF1 548 
by 1M NBI-27914 or ß-adrenergic receptor activation with 1μM isoproterenol induced 549 
changes in mRNA expression of CRF receptors, cognate agonists and brown-adipocytes genes. 550 
*p<0.05 treatment vs. day 0 of differentiation without any treatment, n =4 independent 551 
experiments in triplicate (C-D) Activation of CRF2 with Urocortin 2 or inhibition of CRF1 with 552 
NBI-27914 stimulated mitochondrial biogenesis and cellular respiration as determined by 553 
Cytochrome c oxidase (COX) IV immunostaining (in green; blue: nuclear DAPI staining) and 554 
O2 consumption analysis. *p<0.01 treatment vs. day 0 of differentiation without any treatment, 555 
n =3 independent experiments in triplicate. Black boxes denote genes relevant to white 556 
adipogenesis.  557 
Figure 2 558 
Inhibition of CRF1 or activation of CRF2 in T37i pre-adipocytes promotes brown 559 
adipocyte characteristics. (A) Inhibition of CRF1 by NBI-27914 (1M) or activation of 560 
CRF2 by Urocortin 2 (100nM) induced changes in mRNA expression of CRF receptors and 561 
cognate agonists. (B) Treatment with Urocortin 2 or NBI-27914 induced transcription of key 562 
genes promoting T37i differentiation into brown adipocytes. *p<0.05 treatment vs. day 0 of 563 
differentiation without any treatment, n =4 independent experiments in triplicate.  564 
 565 
Figure 3 566 
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Crhr deletion induces brown-fat characteristics within the white adipose tissue (WAT). 567 
(A) Increased mRNA expression of CRF2 and related ligands as well as increased 568 
immunostaining of Urocortin 2 and CRF2 (in green; blue: nuclear DAPI staining) in the WAT 569 
of  Crhr-/- mice. (B) Changes in the mRNA expression of key genes involved in white or brown 570 
adipocyte differentiation in the WAT of Crhr-/- mice. Restoration of corticosterone levels in 571 
Crhr-/- mice reversed these changes. (C) COXIV and UCP1 protein expression (in green; blue: 572 
nuclear DAPI staining) in Crhr+/+, Crhr-/- and corticosterone-supplemented Crhr-/- mice. 573 
*p<0.05, **p<0.01, vs. Crhr+/+ or corticosterone supplementation. n =5 animals for each 574 
condition. 575 
Figure 4 576 
Lack of CRF1 alters transcriptional levels of key genes in brown adipose tissue. (A) 577 
Brown adipose tissue from Crhr-/- mice shows increased mRNA expression of CRF2 receptors 578 
and cognate agonists. (B) Increased mRNA expression of key genes involved in brown 579 
adipocyte differentiation in the BAT of Crhr-/- mice. Restoration of corticosterone levels in 580 
Crhr-/- mice reverses changes described in A and B. *p<0.05, **, p<0.01 vs. Crhr+/+or 581 
corticosterone-supplemented Crhr-/- mice; n =5 independent experiments in triplicate.  582 
Figure 5 583 
Deletion of crhr induces resistance to diet-induced obesity, an effect reversed by 584 
corticosterone supplementation. (A-L) Crhr+/+, Chrh-/- and Crhr-/- mice supplemented with 585 
corticosterone (Crhr-/- Cort) were fed with a HF diet for 50 days (n=5-6 animals per group). (A) 586 
Body weight gain (% above baseline weight on regular chow diet). & p <0.05, && p<0.01, Crhr -587 
/- vs. Crhr+/+ mice; ##p< 0.01; ###p< 0.001, Crhr-/- Cort vs. Crhr+/+ mice. (B) Fat mass evaluated 588 
by DEXA. (C) Weight of inguinal (PG), mesenteric (MES) and retroperitoneal (RET) fat pads. 589 
(D) Plasma leptin concentration, (E) locomotor activity, (F) cumulative food intake, (G) feed 590 
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efficiency, (H) plasma beta-hydroxybutyrate concentration, (I) fasting homeostatic model 591 
assessment (HOMA), (J) plasma triglycerides concentration, and (K) intraperitoneal glucose 592 
tolerance test (Area under curve analysis: *p<0.05). *p<0.05, **p <0.01, *** p <0.001 vs. 593 
Crhr+/+ and Crhr-/- Cort groups.  594 
 595 
Figure 6 596 
Proposed model illustrating the role of the CRF/urocortin system and of circulating 597 
corticosterone in white adipocytes differentiation. CRF1 and CRF2 intracellular signaling in 598 
white adipocytes determines cell commitment towards divergent differentiation through 599 
autocrine mechanisms. Activation of the CRF2 pathway by local Urocortin stimulates the 600 
differentiation of white adipocytes towards a "brown-like" phenotype, whereas activation of 601 
the CRF1 pathway by local CRF prevents it, thus allowing the expected differentiation 602 
towards a white adipocyte phenotype. CRF1 signaling in the central nervous system stimulates 603 
the activity of the hypothalamo-pituitary-adrenal (HPA) axis and results in corticosterone 604 
secretion. Physiological levels of circulating corticosterone dampen the activation of the CRF2 605 
pathway in adipose tissue and repress the browning of WAT through endocrine mechanisms.  606 
 607 
Supplementary Figure 1 608 
Adult male Crhr-/- mice fed a regular chow diet have a lean phenotype . (A) Body weight 609 
of Crhr+/+ (black circles) and Crhr-/- mice (white circles). (B) Fat mass and (D) lean mass 610 
measured by DEXA. (C) Weight of inguinal (PG), mesenteric (MES) and retroperitoneal 611 
(RET) fat pads. (E) Cumulative food intake. (F) 24-hours locomotor activity during dark and 612 
light phases. (G) Fasting plasma insulin levels and (H) plasma glucose changes in response to 613 
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an intraperitoneal glucose tolerance test. *p <0.05, **p <0.01 vs. CRFr1+/+ mice, n = 6 – 14 614 
animals per group.  615 
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